JAK/STAT signaling pathways and cancer: Minireview

Neoplasma

Volumn 49, Issue 6, 2002, Pages 349-355

  Boudny, V ^a   Kovarik, J ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Cancer; Interferons; Signal transduction; SOCS; STATs

Indexed keywords

IMMUNOLOGIC AGENT; INTERFERON; JANUS KINASE; STAT PROTEIN;

APOPTOSIS; CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL NUCLEUS; GENE TARGETING; HUMAN; ONCOGENE; PATHOGENESIS; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 0036967227     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. AARONSON DS, HORVATH CM. A road map for those who know JAK-STAT. Science 2002; 296:1653-1655.
2. AGARWALA SS, KIRKWOOD JM. Potential uses of interferon alpha 2 as adjuvant therapy in cancer. Ann Surg Oncol 1995; 2: 365-371. Review.
3. AKIRA S. Roles of STAT 3 defined by tissue-specific gene targeting. Oncogene 2000; 19: 2607-2611.
4. COONEY RN. Suppressors of cytokine signalling (SOCS): inhibitors of the JAK/STAT pathway. Shock 2002; 17: 83-90.
5. BOWMAN T, GARCIA R, TURKSON J, JOVE R. STATs in oncogenesis. Oncogene 2000; 19: 2474-2488.
6. BROMBERG JF, WRZESZCZYNSKA MH, DEVGAN G, ZHAO Y, PESTELL RG, ALBANESE C, DARNELL JE JR. STAT 3 as an oncogene. Cell 1999; 98: 295-303.
7. CATLETT-FALCONE R, LANDOWSKI TH, OSHIRO MM, TURKSON J, LEVITZKI A, SAVINO R, CILIBERTO G, MOSCINSKI L, FERNANDEZ-LUNA JL, NUNEZ G, DALTON WS, JOVE R. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115.
8. CHATEERJEE-KISHORE M, KISHORE R, HICKLIN DJ, MARINCOLA FM, FERRONE S. Different requirements for signal transducer and activator of transcription 1 alpha and interferon regulatory factor 1 in the regulation of low molecular mass polypeptide 2 and transporter associated with antigen processing 1 gene expression. J Biol Chem 1998; 273: 16177-16183.
9. CHIN YE, KITAGAWA M, Su WC, You ZH, IWAMOTO Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT 1. Science 1996; 272: 719-722.
10. CHUNG CD, LIAO J, Liao B, RAO X, JAY P, BERTA P, SHUAI K. Specific inhibition of STAT 3 signal transduction by PIAS 3. Science 1997; 278: 1803-1805.
11. DARNELL JE JR. STATs and gene regulation. Science 1997; 277: 1630-1635.
12. DECKER T, KOVARIK P, MEINKE A. GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. J Interferon Cytokine Res 1997; 17: 121-134.
13. DEISS LP, FEINSTEIN E, BERISSI H, COHEN O, KIMCHI A. Identification of a novel serine/threonine kinase and a novel 15 kDa protein as potential mediators of the gamma interferon-induced cell death. Genes Dev 1995; 9: 15-30.
14. DEMAEYER E, DEMAEYER-GIUGNARD J. Interferons and Other Regulatory Cytokines. New York: John Wiley and Sons, 1988.
15. ENDO TA, MASUHARA M, YOKOUCHI M, SUZUKI R, SAKAMOTO H, MITSUI K, MATSUMOTO A, TANIMURA S, OHTSUBO M, MISAWA H, MIYAZAKI T, LEONOR N, TANIGUCHI T, FUJITA T, KANAKURA Y, KOMIYA S, YOSHIMURA. A. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997; 387: 921-924.
16. FRANK DA. STAT signaling in the pathogenesis and treatment of cancer (Review). Mol Med 1999; 5: 432-456.
17. FRANK DA, MAHAJAN S, YUAN H. The chemoprotectant butyrate down-regulates IL-6-induced signaling events in colorectal carcinoma cells. Proc Amer Assoc Cancer Res 1999; 40:318.
18. FUKADA T, HIBI M, YAMANAKA Y, TAKAHASHI-TEZUKA M, FUJI-TANI Y, YMAGUCHI T, NAKAJIMA K, HIRANO T. Two signals are necessary for cell proliferation induced by a cytokine receptor gpl30: involvement of STAT3 in anti-apoptosis. Immunity 1996; 5: 449-460.
19. HAUSER PJ, AGRAWAL D, HACKNEY J, PLEDGER WJ. STAT 3 activation accompanies keratinocyte differentiation. Cell Growth Differ 1998; 9: 847-855.
20. HILTON DJ. Negative regulators of cytokine signal transduction (Review). Cell Mol Life Sci 1999; 55: 1568-1577.
21. IHLE JN. STATs: signal transducers and activators of transcription. Cell 1996; 84: 331-334.
22. ITO S, ANSARI P, SAKATSUME M, DICKENSHEETS H, VAZOUEZ N, DONNELLY RP, LARNER AC, FINBLOOM DS. Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 1999; 93: 1456-1463.
23. KAPLAN MH, SUN YL, HOEY T, GRUSBY MJ. Impaired IL-12 responses and enhanced development of Th2 cells in Stat 4-deficient mice. Nature 1996; 382: 174-177.
24. L expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 1999; 18: 4654-4662.
25. KIRKWOOD JM. Biologic therapy with interferon alpha and beta. Clinical applications: Melanoma. In: DeVita VT, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. Principles and Practice of Oncology. Philadelphia: J.B. Lippincott, 1995: 388-411.
26. KISSELEVA T, BHATTACHARYA S, BRAUNSTEIN J, SCHINDLER CW. Signalling through the JAK/STAT pathway, recent advances a future challenges. Gene 2002; 285: 1-24.
27. KIUCHI N, NAKAJIMA K, ICHIBA M, FUKADA T, NARIMATSU M, MIZUNO K, HIBI M, HIRANO T. STAT 3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med 1999; 189: 63-73.
28. KOLLA V, LINDNER DJ, XIAO W, BORDEN EC, KALVAKOLANU DV. Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT 1 protein in IFN-unresponsive cells. J Biol Chem 1996; 271: 10508-10514.
29. KOVARIK P, MANGOLD M, RAMSAUER K, HEIDARI H, STEINBORN R, ZOTTER A, LEVY DE, MULLER M, DECKER T. Specificity of signaling by STAT 1 depends on SH2 and C-terminal domains that regulate Ser727 phosphorylation, differentially affecting specific target gene expression. EMBO J 2001; 20: 91-100.
30. KREBS DL, HILTON DJ. SOCS: physiological suppressors of cytokine signaling. J Cell Sci 2000; 113: 2813-2819.
31. KREBS DL, HILTON DJ. SOCS Proteins: negative regulators of cytokine signaling. Stem Cells 2001; 19: 378-387.
32. KUMAR A, COMMANE M, FLICKINGER TW, HORVATH CM, STARK GR. Defective TNF-alpha-induced apoptosis in STAT 1-null cells due to low constitutive levels of caspases. Science 1997; 278: 1630-1632.
33. LIX, LEUNG S. QURESHI S, DARNELL JE JR, STARK GR. Formation of STAT1-STAT2 heterodimers and their role in the activation of IRF-1 gene transcription by interferon-alpha. J Biol Chem 1996; 271: 5790-5794.
34. LIU B, LIAO J, RAO X, KUSHNER SA, CHUNG CD, CHANG DD, SHUAI K. Inhibition of Stat 1-mediated gene activation by PIAS 1. Proc Natl Acad Sci USA 1998; 95:10626-10631.
35. LIU X, ROBINSON GW, WAGNER KU, GARRETT L, WYNSHAW-BORIS A, HENNIGHAUSEN L. STAT 5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 1997; 11: 179-186.
36. MATSUMOTO A, MASUHARA M, MITSUI K, YOKOUCHI M, OHTSUBO M, MESAWA H, MEYAJEMA A, YOSHIMURA A. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT 5 pathway and modulates STAT 5 activation. Blood 1997; 89: 3148-3154.
37. MIN W, POBER JS, JOHNSON DR. Kinetically coordinated induction of TAP1 and HLA class I by IFN-gamma: the rapid induction of TAP1 by IFN-gamma is mediated by STAT 1 alpha. J Immunol 1996; 156: 3174-3183.
38. MUHLETHALER-MOTTET A, DI BERARDINO W, OTTEN LA, MACH B. Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between STAT 1 and USF-1. Immunity 1998; 8: 157-166.
39. MUI ALF. The role of STATs in proliferation, differentiation, and apoptosis. Cell Mol Life Sci 1999; 55: 1547-1558.
40. NAKA T, NARAZAKI M, HIRATA M, MATSUMOTO T, MINAMOTO S, AONO A, NISHIMOTO N, KAJITA T, TAGA T, YOSHIZAKI K, AKIRA S, KlSHIMOTO T. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997; 387: 924-929.
41. NICHOLSON SE, WILLSON TA, FARLEY A, STARR R, ZHANG JG, BACA M, ALEXANDER WS, METCALF D, HILTON DJ, NICOLA NA. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J 1999; 18: 375-385.
42. O'SHEA JJO, GADINA M, SCHREIBER RD. Cytokine signaling in 2002: New surprises in the Jak/Stat Pathway. Cell 2002; 109: 121-131.
43. PANSKY A, HILDEBRAND P, FASLER-KAN E, BASELGIA L, KETTERER S, BEGLINGER C, HEIM MH. Defective JAK-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 2000; 85: 720-725.
44. ROSENBERG SA. Biologic Therapy. In: DeVita DT, Hellman S, Rosenberg SA, editors. Cancer. Principles and Practice of Oncology. Philadelphia: J.B. Lippincott, 2001: 307-326.
45. SAKAMOTO H, YASUKAWA H, MASUHARA M, TANIMURA S, SASAKI A, YUGE K, OHTSUBO M, OHTSUKA A, FUJITA T, OHTA T, FURUKAWA Y, IWASE S, YAMADA H, YOSHIMURA A. A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons. Blood 1998; 92: 1668-1676.
46. SCHINDLER C, DARNELL JE JR. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway (Review). Annu Rev Biochem 1995; 64: 621-651.
47. SINIBALDI D, WHARTON W, TURKSON J, BOWMAN T, PLEDGER WJ, JOVE R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signalling. Oncogene 2000; 19:5419-5427.
48. SKOV S, NIELSEN M, BREGENHOLT S, ODUM N, CLAESSON MH. Activation of STAT 3 is involved in the induction of apoptosis after ligation of major histocompatibility complex class I molecules on human Jurkat T cells. Blood 1998; 91: 3566-3573.
49. STARR R, WILLSON TA, VINEY EM, MURRAY LJ, RAYNER JR, JENKINS BJ, GONDA TJ, ALEXANDER WS, METCALF D, NICOLA NA, HILTON DJ. A family of cytokine-inducible inhibitors of signaling. Nature 1997; 387: 917-921.
50. TAKEDA K, KAISHO T, YOSHIDA N, TAKEDA J, KISHIMOTO T, AKIRA S. STAT3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterisation of T cell-specific STAT3-deficient mice. J Immunol 1998; 161: 4652-4660.
51. TURKSON J, JOVE R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000; 19: 6613-6626.
52. VON STAMM U, BROCKER EB, VON DEPKA PRONDZINSKI M, RUITER DJ, RUMKE P, BRODING C, CARREL S, LEJEUNE FJ. Effects of systemic interferon-alpha (IFN-alpha) on the antigenic phenotype of melanoma metastases. EORTC melanoma group cooperative study No. 18852. Melanoma Res 1993; 3: 173-180.
53. WALTER MJ, LOOK DC, TIDWELL RM, ROSWIT WT, HOLTZMAN MJ. Targeted inhibition of interferon-gamma-dependent intercellular adhesion molecule-1 (ICAM-1) expression using dominant-negative Stat 1. J Biol Chem 1997; 272: 28582-28589.
54. WEN Z, ZHONG Z, DARNELL JE JR. Maximal activation of transcription by STAT 1 and STAT 3 requires both tyrosine and serine phosphorylation. Cell 1995; 82: 241-250.
55. WONG LH, KRAUER KG, HATZINISIRIOU I, ESTCOURT MJ, HERSEY P, TAM ND, EDMONDSON S, DEVENISH RJ, RALPH SJ. Interferon-resistant human melanoma cells are deficient in ISGF 3 components, STAT 1, STAT 2, and p48-ISGF 3gamma. J Biol Chem 1997; 272: 28779-28785.
56. XU X, FU XY, PLATE J, CHONG AS. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT 1 protein for up-regulation of Fas and FasL expression. Cancer Res 1998; 58: 2832-2837.
57. YAFFE MB, CANTLEY LC. Signal transduction. Grabbing phosphoproteins. Nature 1999; 402: 30-31.
58. YAMADA H, OCHI K, NAKADA S, NEMOTO T, HORIGUCHI-YAMADA J. Changes of cell cycle-regulating genes in interferon-treated Daudi cells. Mol Cell Biochem 1994; 136: 117-123.
59. YOSHIMURA A, OHKUBO T, KIGUCHI T, JENKINS NA, GILBERT DJ, COPELAND NG, HARA T, MIYAJIMA A. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 1995; 14:2816-2826.
60. Yu CL, MEYER DJ, CAMPBELL GS, LARNER AC, CARTER-SU C, SCHWARTZ J, JOVE R. Enhanced DNA-binding activity of a STAT 3-related protein in cells transformed by the Src oncoprotein. Science 1995; 269: 81-83.
61. ZUSHI S, SHINOMURA Y, KIYOHARA T, MIYAZAKI YM, KONDO S, SUGIMACHI M, HIGASHIMOTO Y, KANAYAMA S, MATSUZAWA Y. STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer 1998; 78: 326-330.